Some better-ranked stocks from the broader medical space are DexCom, Inc.
Image Source: Zacks Investment Research Zacks Rank & Key PicksĬurrently, Surmodics carries a Zacks Rank #3 (Hold). Shares of the company have gained 38.8% in the past year compared with the industry’s 4.9% growth and the S&P 500's 31.5% rise. The same month, the company acquired the privately-held Vetex Medical Limited and expanded its thrombectomy portfolio with a second FDA 510(k)-cleared device, the ReVene Thrombectomy Catheter. Surmodics, in July, announced the successful first patient use of Pounce Thrombectomy System, where 30 cm of subacute thrombus was removed and blood flow successfully restored. In August, the company reported the third-quarter fiscal 2021 results, where it announced the completion of the premarket approval submission for SurVeil drug-coated balloon and the receipt of the FDA 510(k) clearance on the expanded indication for the Pounce Thrombectomy System for use in vessels as small as 3.5 mm. Of late, Surmodics has witnessed a few notable developments across its business. 018 RX PTA Dilatation Catheter is expected to significantly boost Surmodics’ global business. Given the market potential, the successful first patient usage of the Sublime Radial Access. Per management, due to the lack of reliable tools limiting the ability to standardize on a radial first approach, the expansion of the company’s portfolio of radial access devices is likely to allow more physicians to adopt a radial-first strategy. This is likely to enhance the suite of the current devices available for the minimal arterial access lower extremity intervention procedures. 018 RX PTA Dilatation Catheter is expected to aid in performing more complex interventions which were earlier not possible. Per an expert associated with the procedures, the Sublime Radial Access. 018 RX PTA Dilatation Catheter has been designed to deliver enhanced pushability, trackability and crossability on an RX platform. The latest addition to Surmodics’ Sublime radial access platform enables above- or below-the-knee access via a transradial approach by providing the longest working length (220 cm) currently available in the market. With the latest successful first patient usage, Surmodics is anticipated to solidify its foothold in the global Medical Devices business. However, the device is contraindicated (suggesting or indicating that it should not be used) in the treatment of coronary arteries and the neurovasculature. 018 RX PTA Dilatation Catheter is indicated for the PTA dilation of peripheral vasculature stenosis in various arteries and the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. 014 RX PTA Dilatation Catheter.įor investors’ note, the Sublime Radial Access. The catheter, which received the FDA’s 510(k) clearance in June 2021, is the latest addition to the company’s Sublime radial access platform and joins the Sublime radial access guide sheath and the Sublime Radial Access. 018 RX PTA (percutaneous transluminal angioplasty) Dilatation Catheter. SRDX recently announced the successful first clinical usage of its Sublime Radial Access.
0 kommentar(er)
